Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization FDA accepts Company’s Data Access Plan to determine potential new clinical endpoints to support Emergency Use Authorization

The post Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 appeared first on Bio Tech Winners.

Read MoreBio Tech Winners